Clinical Trial Update: Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing oral DLBS1033 as adjunctive therapy for acute ischemic stroke has completed, examining its impact on inflammatory biomarkers and patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• DLBS1033 (DLBS1033)

Snippet

Sponsor: Universitas Sebelas Maret | Conditions: Ischemic Stroke, Acute | Phase 4 | Status: COMPLETED